Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell therapy in demyelinating diseases.

Claire Rice1, Christopher Halfpenny, Neil Scolding

  • 1University of Bristol Institute of Clinical Neurosciences, Department of Neurology, Frenchay Hospital, Bristol, BS16 1LE, United Kingdom.

Neurorx : the Journal of the American Society for Experimental Neurotherapeutics
|February 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Encephalitic rabies following cat bites: two cases in northern Uganda.

Practical neurology·2026
Same author

Primary central nervous system vasculitis: an update.

Journal of neurology·2026
Same author

Optimal strategies for treatment discontinuation in MOG antibody-associated disease.

Brain : a journal of neurology·2026
Same author

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2025
Same author

Trajectories of change in experiences of multiple sclerosis: insights from an online group psychological intervention.

Disability and rehabilitation·2025
Same journal

Pediatric neurotherapy.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics·2013
Same journal

Drug development in critical times.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics·2006
Same journal

Spinal muscular atrophy: a test case for drug development in orphan diseases.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics·2006
Same journal

Community neurorehabilitation: a synthesis of current evidence and future research directions.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics·2006
Same journal

Issues in selecting outcome measures to assess functional recovery after stroke.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics·2006
Same journal

Behavioral tests for preclinical intervention assessment.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics·2006
See all related articles

Developing cell-based therapies for multiple sclerosis (MS) faces challenges like widespread lesions and inflammation. However, focused damage to myelin and successful experimental repair offer hope for future remyelination strategies.

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Cell Therapy

Background:

  • Multiple sclerosis (MS) is characterized by CNS lesions, axon loss, astrocytosis, and inflammation.
  • Early MS damage often focuses on oligodendrocytes and myelin.
  • Extensive knowledge exists on oligodendrocyte biology and successful experimental myelin repair.

Purpose of the Study:

  • To review clinical and biological challenges of MS in the context of cell therapies.
  • To discuss the neuroscientific background for developing myelin repair strategies.
  • To identify unresolved difficulties and speculate on future remyelinating therapies.

Main Methods:

  • Review of existing clinical and biological data on multiple sclerosis.
  • Analysis of neuroscientific literature on oligodendrocyte biology and myelin repair.

Related Experiment Videos

  • Synthesis of recent experimental findings to project future therapeutic developments.

    • Main Results:

    • Multiple sclerosis presents significant hurdles for cell-based therapies due to widespread neurodegeneration and inflammation.
    • The specific vulnerability of oligodendrocytes and myelin in early MS, coupled with successful repair models, provides a basis for therapeutic optimism.
    • Key challenges remain in resolving complex pathological processes and translating experimental successes into clinical applications.

    Conclusions:

    • Despite challenges, cell-based therapies hold potential for treating multiple sclerosis by targeting myelin repair.
    • Further research is needed to overcome existing obstacles and advance the development of effective remyelinating strategies.
    • Future remyelinating therapies are likely to emerge from continued investigation into experimental findings and unresolved clinical issues.